DexCom, Inc.
DXCM
$61.14
$1.813.05%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1.19B | 1.26B | 1.21B | 1.16B | 1.04B |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1.19B | 1.26B | 1.21B | 1.16B | 1.04B |
| Cost of Revenue | 441.60M | 466.90M | 477.90M | 468.30M | 447.00M |
| Gross Profit | 750.30M | 792.70M | 731.40M | 688.80M | 589.00M |
| SG&A Expenses | 349.70M | 321.50M | 331.40M | 328.00M | 310.10M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 936.60M | 936.60M | 966.80M | 944.50M | 902.30M |
| Operating Income | 255.30M | 323.00M | 242.50M | 212.60M | 133.70M |
| Income Before Tax | 269.50M | 340.70M | 352.30M | 241.10M | 154.30M |
| Income Tax Expenses | 70.00M | 73.40M | 68.50M | 61.30M | 48.90M |
| Earnings from Continuing Operations | 199.50M | 267.30M | 283.80M | 179.80M | 105.40M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 199.50M | 267.30M | 283.80M | 179.80M | 105.40M |
| EBIT | 255.30M | 323.00M | 242.50M | 212.60M | 133.70M |
| EBITDA | 322.40M | 388.20M | 306.10M | 275.60M | 193.70M |
| EPS Basic | 0.52 | 0.69 | 0.73 | 0.46 | 0.27 |
| Normalized Basic EPS | 0.44 | 0.55 | 0.56 | 0.38 | 0.25 |
| EPS Diluted | 0.51 | 0.68 | 0.70 | 0.45 | 0.27 |
| Normalized Diluted EPS | 0.43 | 0.53 | 0.54 | 0.37 | 0.24 |
| Average Basic Shares Outstanding | 385.10M | 386.70M | 391.10M | 392.10M | 391.10M |
| Average Diluted Shares Outstanding | 393.60M | 398.90M | 407.40M | 408.20M | 407.50M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |